Triptans: where things stand
- PMID: 20842600
- DOI: 10.1007/s11940-010-0082-9
Triptans: where things stand
Abstract
Triptans, selective serotonin receptor agonists, were developed almost 20 years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicated. This article reviews the development of triptans, discusses reasons for their success or failure, and examines the limitations and controversies surrounding this class of medication.
Similar articles
-
Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.Cephalalgia. 2002 Oct;22(8):633-58. doi: 10.1046/j.1468-2982.2002.00404.x. Cephalalgia. 2002. PMID: 12383060
-
Topics in migraine management: a survey of headache specialists highlights some controversies.Neurol Clin. 2001 Feb;19(1):1-21. doi: 10.1016/s0733-8619(05)70003-7. Neurol Clin. 2001. PMID: 11471758 Review.
-
Triptans in the treatment of basilar migraine and migraine with prolonged aura.Headache. 2001 Nov-Dec;41(10):981-4. doi: 10.1046/j.1526-4610.2001.01192.x. Headache. 2001. PMID: 11903526
-
Efficacy of frovatriptan as compared to other triptans in migraine with aura.J Headache Pain. 2015;16:514. doi: 10.1186/s10194-015-0514-8. Epub 2015 Apr 1. J Headache Pain. 2015. PMID: 25916333 Free PMC article.
-
Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.Prog Brain Res. 2020;255:99-121. doi: 10.1016/bs.pbr.2020.05.010. Epub 2020 Jun 12. Prog Brain Res. 2020. PMID: 33008517 Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous